Showing results (271-280 of 305) with videos related to
Sort By:
Pageof 31
The Journal of Infection|October 18, 2023
Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeysCraig Fenwick, Priscilla Turelli, Yoan Duhoo, et al.Genome Medicine|December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparibAlan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.Journal for Immunotherapy of Cancer|June 15, 2022
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumabGeoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2020
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)Neesha C Dhani, Hal W Hirte, Lisa Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular CharacterizationStephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 7, 2021
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced CancerCamilla Zimmermann, Ashley Pope, Breffni Hannon, et al.Cancer Discovery|February 23, 2024
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid TumorsEric Y Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui Amy Liu, et al.JAMA Oncology|November 18, 2017
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical CarcinomaStephanie Lheureux, Marcus O Butler, Blaise Clarke, et al.Journal for Immunotherapy of Cancer|August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumorsKirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.The Science of the Total Environment|October 24, 2022
Trajectories of nutrients concentrations and ratios in the French coastal ecosystems: 20 years of changes in relation with large-scale and local driversArnaud Lheureux, Valérie David, Yolanda Del Amo, et al.Pageof 31